Photo from wikipedia
Immune disorder is a key trigger of recurrent spontaneous abortion (RSA); meanwhile, tumour necrosis factor inhibitor (TNFi) is a fundamental therapeutic for multiple immune and inflammatory diseases. Hence, this real‐world… Click to show full abstract
Immune disorder is a key trigger of recurrent spontaneous abortion (RSA); meanwhile, tumour necrosis factor inhibitor (TNFi) is a fundamental therapeutic for multiple immune and inflammatory diseases. Hence, this real‐world study aimed to explore the efficacy and safety of TNFi combined with intravenous immunoglobin (IVIG) and heparin therapy in RSA patients.
Keywords:
necrosis factor;
combined intravenous;
spontaneous abortion;
recurrent spontaneous;
tumour necrosis;
factor inhibitor
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!